TrialCancer research communications2024

Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study.

Clinton Yam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.